Research ExplorerPublicationsInitial experience and procedural efficacy of pulmonary vein...

Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward?

Standard

Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward? / Mathew, Shibu; Rottner, Laura; Warneke, Laura; Maurer, Tilman; Lemes, Christine; Hashiguchi, Naotaka; Reißmann, Bruno; Goldmann, Britta; Ouyang, Feifan; Kuck, Karl-Heinz; Metzner, Andreas; Rillig, Andreas.

In: ACTA CARDIOL, Vol. 75, No. 8, 12.2020, p. 754-759.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mathew, S, Rottner, L, Warneke, L, Maurer, T, Lemes, C, Hashiguchi, N, Reißmann, B, Goldmann, B, Ouyang, F, Kuck, K-H, Metzner, A & Rillig, A 2020, 'Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward?', ACTA CARDIOL, vol. 75, no. 8, pp. 754-759. https://doi.org/10.1080/00015385.2019.1677373

APA

Mathew, S., Rottner, L., Warneke, L., Maurer, T., Lemes, C., Hashiguchi, N., Reißmann, B., Goldmann, B., Ouyang, F., Kuck, K-H., Metzner, A., & Rillig, A. (2020). Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward? ACTA CARDIOL, 75(8), 754-759. https://doi.org/10.1080/00015385.2019.1677373

Vancouver

Mathew S, Rottner L, Warneke L, Maurer T, Lemes C, Hashiguchi N et al. Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward? ACTA CARDIOL. 2020 Dec;75(8):754-759. https://doi.org/10.1080/00015385.2019.1677373

Bibtex

@article{499a4962eaaa424f9edf5354ad99d91d,
title = "Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward?",
abstract = "Background: Cryoballoon (CB)-based pulmonary vein isolation (PVI) is an established treatment modality for patients suffering from paroxysmal or persistent atrial fibrillation (AF). Recently, the novel fourth-generation cryoballoon (CB4) was introduced which mainly provides a 40% shorter distal tip as compared to the second-generation cryoballoon (CB2). This two-centre analysis sought to assess the primary efficacy of the 28 mm CB4 for PVI and the feasibility of real-time signal recordings from the PVs considering the time-to-isolation (TTI).Methods and results: Eighty-four patients with paroxysmal or short-standing persistent AF underwent CB4-based PVI at two different hospitals. Individual freeze-cycle duration was set at TTI + 120 seconds. No bonus freeze was applied. A total of 331 pulmonary veins (PVs) including five left common PVs were identified and all PVs were successfully isolated. Mean freeze-cycle duration was 165.7 ± 31.5 seconds. The mean minimal CB temperature was -45.6 ± 7.6 °C with a real-time PVI visualisation rate of 78% (67/84 (79.8%) RSPVs, 55/84 (65.5%) RIPVs, 67/79 (84.8%) LSPVs, 66/79 (83.5%) LIPVs and 2/5 (40%) LCPV). Transient phrenic nerve palsy occurred in 2/84 (2.4%) patients during cryo-application along the RSPV.Conclusions: The novel CB4 provides both, a high acute efficacy and a high rate of real time electrical PV-recordings, thus facilitating individual ablation strategies based on TTI.",
keywords = "Atrial Fibrillation/physiopathology, Cardiac Catheters, Cryosurgery/instrumentation, Equipment Design, Female, Heart Rate/physiology, Humans, Male, Middle Aged, Operative Time, Pulmonary Veins/surgery, Time Factors, Treatment Outcome",
author = "Shibu Mathew and Laura Rottner and Laura Warneke and Tilman Maurer and Christine Lemes and Naotaka Hashiguchi and Bruno Rei{\ss}mann and Britta Goldmann and Feifan Ouyang and Karl-Heinz Kuck and Andreas Metzner and Andreas Rillig",
year = "2020",
month = dec,
doi = "10.1080/00015385.2019.1677373",
language = "English",
volume = "75",
pages = "754--759",
journal = "ACTA CARDIOL",
issn = "0001-5385",
publisher = "Acta Cardiologica",
number = "8",

}

RIS

TY - JOUR

T1 - Initial experience and procedural efficacy of pulmonary vein isolation using the fourth-generation cryoballoon - a step forward?

AU - Mathew, Shibu

AU - Rottner, Laura

AU - Warneke, Laura

AU - Maurer, Tilman

AU - Lemes, Christine

AU - Hashiguchi, Naotaka

AU - Reißmann, Bruno

AU - Goldmann, Britta

AU - Ouyang, Feifan

AU - Kuck, Karl-Heinz

AU - Metzner, Andreas

AU - Rillig, Andreas

PY - 2020/12

Y1 - 2020/12

N2 - Background: Cryoballoon (CB)-based pulmonary vein isolation (PVI) is an established treatment modality for patients suffering from paroxysmal or persistent atrial fibrillation (AF). Recently, the novel fourth-generation cryoballoon (CB4) was introduced which mainly provides a 40% shorter distal tip as compared to the second-generation cryoballoon (CB2). This two-centre analysis sought to assess the primary efficacy of the 28 mm CB4 for PVI and the feasibility of real-time signal recordings from the PVs considering the time-to-isolation (TTI).Methods and results: Eighty-four patients with paroxysmal or short-standing persistent AF underwent CB4-based PVI at two different hospitals. Individual freeze-cycle duration was set at TTI + 120 seconds. No bonus freeze was applied. A total of 331 pulmonary veins (PVs) including five left common PVs were identified and all PVs were successfully isolated. Mean freeze-cycle duration was 165.7 ± 31.5 seconds. The mean minimal CB temperature was -45.6 ± 7.6 °C with a real-time PVI visualisation rate of 78% (67/84 (79.8%) RSPVs, 55/84 (65.5%) RIPVs, 67/79 (84.8%) LSPVs, 66/79 (83.5%) LIPVs and 2/5 (40%) LCPV). Transient phrenic nerve palsy occurred in 2/84 (2.4%) patients during cryo-application along the RSPV.Conclusions: The novel CB4 provides both, a high acute efficacy and a high rate of real time electrical PV-recordings, thus facilitating individual ablation strategies based on TTI.

AB - Background: Cryoballoon (CB)-based pulmonary vein isolation (PVI) is an established treatment modality for patients suffering from paroxysmal or persistent atrial fibrillation (AF). Recently, the novel fourth-generation cryoballoon (CB4) was introduced which mainly provides a 40% shorter distal tip as compared to the second-generation cryoballoon (CB2). This two-centre analysis sought to assess the primary efficacy of the 28 mm CB4 for PVI and the feasibility of real-time signal recordings from the PVs considering the time-to-isolation (TTI).Methods and results: Eighty-four patients with paroxysmal or short-standing persistent AF underwent CB4-based PVI at two different hospitals. Individual freeze-cycle duration was set at TTI + 120 seconds. No bonus freeze was applied. A total of 331 pulmonary veins (PVs) including five left common PVs were identified and all PVs were successfully isolated. Mean freeze-cycle duration was 165.7 ± 31.5 seconds. The mean minimal CB temperature was -45.6 ± 7.6 °C with a real-time PVI visualisation rate of 78% (67/84 (79.8%) RSPVs, 55/84 (65.5%) RIPVs, 67/79 (84.8%) LSPVs, 66/79 (83.5%) LIPVs and 2/5 (40%) LCPV). Transient phrenic nerve palsy occurred in 2/84 (2.4%) patients during cryo-application along the RSPV.Conclusions: The novel CB4 provides both, a high acute efficacy and a high rate of real time electrical PV-recordings, thus facilitating individual ablation strategies based on TTI.

KW - Atrial Fibrillation/physiopathology

KW - Cardiac Catheters

KW - Cryosurgery/instrumentation

KW - Equipment Design

KW - Female

KW - Heart Rate/physiology

KW - Humans

KW - Male

KW - Middle Aged

KW - Operative Time

KW - Pulmonary Veins/surgery

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1080/00015385.2019.1677373

DO - 10.1080/00015385.2019.1677373

M3 - SCORING: Journal article

C2 - 31630633

VL - 75

SP - 754

EP - 759

JO - ACTA CARDIOL

JF - ACTA CARDIOL

SN - 0001-5385

IS - 8

ER -